A parallel group comparison of tenoxicam and piroxicam in patients with ankylosing spondylitis

A parallel group comparison of tenoxicam and piroxicam in patients with ankylosing spondylitis

Tenoxicam (20 mg/day) and piroxicam (20 mg/day) were compared in a double-blind, parallel group study over 4 weeks in 30 patients with ankylosing spondylitis. Both tenoxicam and piroxicam reduced spinal pain, but the improvement was greater with piroxicam. Tenoxicam and piroxicam were equally effect...

Ausführliche Beschreibung

Bibliographische Detailangaben
Veröffentlicht in:Interim guidelines for the control of infections with Vero cytotoxin producing Escherichia coli (VTEC). Subcommittee of the PHLS Working Group on Vero cytotoxin producing Escherichia coli (VTEC). - 1995. - 4(1986), 7 vom: 11., Seite 457-62
1. Verfasser: Bird, H A (VerfasserIn)
Weitere Verfasser: Le Gallez, P, Astbury, C, Looi, D, Wright, V
Format: Aufsatz
Sprache:English
Veröffentlicht: 1986
Zugriff auf das übergeordnete Werk:Interim guidelines for the control of infections with Vero cytotoxin producing Escherichia coli (VTEC). Subcommittee of the PHLS Working Group on Vero cytotoxin producing Escherichia coli (VTEC)
Schlagworte:Clinical Trial Comparative Study Controlled Clinical Trial Journal Article Randomized Controlled Trial Research Support, Non-U.S. Gov't Thiazines Piroxicam 13T4O6VMAM tenoxicam Z1R9N0A399